Our mission is to reduce colon cancer deaths through the early, patient-friendly detection of both precancer and cancer.

Overview
  • Patient-friendly screening test for the early detection and prevention of colon cancer
  • DNA test detects precancer and cancer
  • Major unmet need > U.S. market opportunity > $1 billion
  • Exclusive intellectual property
  • Proven management team with clinical trial success in cancer screening tests
2009 Execution
Focus on Product Development   Plan Clinical Trial   Create Performance Culture
  • Simplified collection device
  • Simplified test, markers and lab
    workflow
  • Superior quantitative detection
    chemistry
  • Developed detailed clinical trial plan
  • Engaged with FDA regarding trial
    design
  • Developed budget
  • Recruited top-tier investigators
  • Hired world-class chief science officer
  • Rebuilt R&D team
  • Mayo Clinic R&D collaboration
  • Improved intellectual property portfolio
  • Strengthened balance sheet

Exact's Powerful, Preventive Screening Tool

Product Milestones

2010 Priorities
Product Development   Clinical Trial Planning   Market Development
  • Refine assay components
  • Conduct pre-clinical validation
    study
  • Complete quality system
  • Engage clinical research
    organization, or CRO
  • Finalize clinical trial study design
  • Engage clinical trial sites
  • Secure institutional review board
    (IRB) approvals
  • Develop go-to-market plan
  • Engage key physician and payor leaders
  • Evaluate ex-US market